[go: up one dir, main page]

AR032066A1 - Agente para tratamiento terapeutico y profilactico del dolor neuropatico - Google Patents

Agente para tratamiento terapeutico y profilactico del dolor neuropatico

Info

Publication number
AR032066A1
AR032066A1 ARP010106055A ARP010106055A AR032066A1 AR 032066 A1 AR032066 A1 AR 032066A1 AR P010106055 A ARP010106055 A AR P010106055A AR P010106055 A ARP010106055 A AR P010106055A AR 032066 A1 AR032066 A1 AR 032066A1
Authority
AR
Argentina
Prior art keywords
group
atoms
therapeutic
carbon atoms
neuropathic pain
Prior art date
Application number
ARP010106055A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR032066A1 publication Critical patent/AR032066A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un medicamento para el tratamiento terapéutico y/o profiláctico del dolor neuropático que comprende un compuesto representado por la formula general (1) o una sal farmacéuticamente aceptable del mismo como un ingrediente activo, en donde R1 representa un átomo de hidrogeno o un grupo hidroxilo; R2 representa un átomo de hidrogeno o un grupo alquilo que posee 1 a 3 átomos de carbono; R3 representa un grupo fenilo el cual puede poseer 1 a 3 átomos o sustituyentes seleccionados del grupo que consiste de un átomo halogeno, un grupo hidroxilo, un grupo alquilo que posee 1 a 3 átomos de carbono, y un grupo alcoxilo que posee 1 a 3 átomos de carbono, o representa -NH-R4 en donde R4 representa un grupo fenilo que pueden poseer 1 a 3 átomos o sustituyentes seleccionados del grupo que consiste en un átomo de halogeno, un grupo hidroxilo, un grupo alquilo que posee 1 a 3 átomos de carbono, y un grupo alcoxilo que posee 1 a 3 átomos de carbono o átomo de hidrogeno, y n representa 0 o 1.
ARP010106055A 2000-12-28 2001-12-27 Agente para tratamiento terapeutico y profilactico del dolor neuropatico AR032066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000400679 2000-12-28

Publications (1)

Publication Number Publication Date
AR032066A1 true AR032066A1 (es) 2003-10-22

Family

ID=18865226

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010106055A AR032066A1 (es) 2000-12-28 2001-12-27 Agente para tratamiento terapeutico y profilactico del dolor neuropatico

Country Status (11)

Country Link
US (1) US7608636B2 (es)
EP (1) EP1356812B1 (es)
JP (1) JPWO2002053153A1 (es)
KR (1) KR100823668B1 (es)
CN (1) CN1484527A (es)
AR (1) AR032066A1 (es)
AT (1) ATE431142T1 (es)
CA (1) CA2433039C (es)
DE (1) DE60138733D1 (es)
MX (1) MXPA03005889A (es)
WO (1) WO2002053153A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521000A1 (en) * 2003-04-03 2004-10-21 Kyowa Hakko Kogyo Co., Ltd. Preventive and/or therapeutic agent for neuropathic pain
US7283839B2 (en) 2004-04-14 2007-10-16 Curitel Communications, Inc. Wireless communicating terminal for providing integrated messaging service and method thereof
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
ITMI20070770A1 (it) 2007-04-16 2008-10-17 Brane Discovery S R L Impiego di dimiracetam nel trattamento del dolore cronico
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
PL389364A1 (pl) 2009-10-23 2011-04-26 Uniwersytet Jagielloński Nowe zastosowanie pochodnych 2-pirolidonu
LV14346B (lv) * 2009-11-05 2011-07-20 Grindeks, A/S 2-(4-Fenil-5-metil-2-oksopirolidin-1-il)-acetamīda 4R,5S-enantiomērs ar nootropo aktivitāti
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US9662347B2 (en) 2010-05-11 2017-05-30 Gachon University Of Industry-Academic Cooperation Foundation Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
PL244071B1 (pl) * 2019-01-07 2023-11-27 Univ Jagiellonski Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1039113A (en) 1964-08-06 1966-08-17 Ucb Sa New n-substituted lactams
JPS4219093Y1 (es) 1965-11-27 1967-11-04
IT1045043B (it) 1975-08-13 1980-04-21 Isf Spa Derivati pirrolidinici
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
CU21107A3 (es) 1978-02-10 1988-02-01 Hoffmann La Roche Pyrrolidines derivatives
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
CH657527A5 (de) * 1980-02-13 1986-09-15 Ciba Geigy Ag Verwendung von zentralnervoes-wirksamen verbindungen in einem mittel, welches zur verhinderung oder linderung von nebenwirkungen bestimmt ist.
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
JPS625404A (ja) 1985-07-01 1987-01-12 Shinko Electric Co Ltd 信号レベル変換装置
GB8609033D0 (en) * 1986-04-14 1986-05-21 Ucb Sa Pharmaceutical compositions
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
JPH0779442B2 (ja) 1989-07-14 1995-08-23 日本テレビ放送網株式会社 雑音減少回路
JPH04160496A (ja) 1990-10-23 1992-06-03 Sharp Corp 自動販売機の物品搬出機構
US5232700A (en) * 1990-11-14 1993-08-03 The Administrators Of The Tulane Educational Fund Methods of prophylaxis and treatment of herpes simplex lesions utilizing piracetam as the active ingredient
JPH04219093A (ja) 1990-12-19 1992-08-10 Matsushita Electric Ind Co Ltd 磁気記録再生装置
JP3388778B2 (ja) 1991-05-02 2003-03-24 第一製薬株式会社 脳血管性痴呆改善剤
CA2067614C (en) 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
ZA923134B (en) 1991-05-02 1993-01-27 Daiichi Seiyaku Co Agent for improving dementia
NO179903C (no) 1992-06-19 1997-01-08 Daiichi Seiyaku Co Fremgangsmåte for fremstilling av et halogenacetamidderivat samt et pyrrolidinylacetamidderivat
GB9505692D0 (en) * 1995-03-21 1995-05-10 Glaxo Group Ltd Chemical compounds
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
CN1080805C (zh) * 1995-08-04 2002-03-13 海德罗－弗罗控股公司 活塞阀
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
US5551846A (en) 1995-12-01 1996-09-03 Ford Motor Company Scroll compressor capacity control valve
EP0953356A4 (en) 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
KR20010021897A (ko) 1997-07-15 2001-03-15 스즈키 다다시 건망증의 예방 또는 치료약
TW544311B (en) 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6349442B1 (en) * 1999-06-23 2002-02-26 Advanced Prosthetic Technologies, Inc. Brush tip for a motorized toothbrush
MXPA02005275A (es) 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration

Also Published As

Publication number Publication date
KR20040025882A (ko) 2004-03-26
US7608636B2 (en) 2009-10-27
CA2433039C (en) 2010-06-08
DE60138733D1 (de) 2009-06-25
CA2433039A1 (en) 2002-07-11
WO2002053153A1 (en) 2002-07-11
EP1356812A4 (en) 2006-04-12
US20040063776A1 (en) 2004-04-01
MXPA03005889A (es) 2005-02-14
ATE431142T1 (de) 2009-05-15
EP1356812A1 (en) 2003-10-29
KR100823668B1 (ko) 2008-04-21
CN1484527A (zh) 2004-03-24
JPWO2002053153A1 (ja) 2004-04-30
EP1356812B1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
AR032066A1 (es) Agente para tratamiento terapeutico y profilactico del dolor neuropatico
RU2221790C2 (ru) Новые производные пиридазина и лекарственные средства, содержащие их в качестве эффективных ингредиентов
DE69529670D1 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
RU2002124873A (ru) Глюкопиранозилоксибензилбензольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для получения указанных производных
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AR030816A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
GB0112348D0 (en) Compounds
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
AR039936A1 (es) Formulacion farmaceutica de liberacion modificada
CA2336412A1 (en) Medicament for treatment of diabetes
AR023264A1 (es) Derivados de eritromicina
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
EA200100916A1 (ru) Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
KR900018091A (ko) 진경제
CA2510468A1 (en) Novel 2,4-diamino-1,3,5-triazine derivative
MX9305719A (es) Agente antiarritmico.
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
SE0002739D0 (sv) New use
BR0102940A (pt) Agente para o tratamento de doença de parkinson compreendendo um agente de melhora da função de astrócitos como ingrediente ativo
NO20070421L (no) Radiosensitiviserende middel
ES2123808T3 (es) Derivado de acilfenilglicina y agente profilactico y curativo para enfermedades causadas por una actividad acrecentada de colagenasa, que contiene dicho compuesto como ingrediente activo.
TW200510379A (en) 1, 4-disubstituted piperidine compounds, their preparation and use as medicaments
NO20032411D0 (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens

Legal Events

Date Code Title Description
FB Suspension of granting procedure